Pathogenesis and control of chronic infections

 Philippe VAN DE PERRE

 PCCI - UMR 1058

 60 rue de Navacelles, 34394 Montpellier

Phone: +33 4 34 35 91 11

Email: p-van_de_perre@chu-montpellier.fr

Website

UMR 1058 is a multidisplinary research unit with researchers from the:

-        Institut National de la Sante et de la Recherche Médicale (INSERM)

-        Université de Montpellier (UM)

-        Etablissement Français du Sang (EFS)

-        CHU de Montpellier (Montpellier University Hospital, France)

It is one of the very few in France and Europe to be fully dedicated to persistent infectious agents.  Their expertise in the infection research domain enables UMR 1058 to carry out translational research on HIV transmission and associated chronic infections from the fundamental to the clinical phase.  The unit is involved in national projects with regional hospitals and international projects with developing countries in the south (Sub-Saharan Africa and South-East Asia).

There are two teams and they work in close collaboration with each other to develop innovative diagnostic concepts and new approaches in prevention and healthcare by exploring the pathogenesis.

·       Team 1 : Diagnostic and Therapeutic Innovation (Team leaders: C. Fournier-Wirth et E. Tuaillon)

·       Team 2: Pathogenesis and  new approaches in prevention and care (Team leader: N. Nagot)

It  also hosts two start-up companies OMUNIS (managed by P-A. Rubbo) and PAN-VIR Therapeutics (managed by J-M. Jacqué).

UMR 1058 has obtained support and fundings from ANRS, ANR, European Union (EDCTP, FP7), NIH/NIDA and several foundations.

Keywords: chronic infections, diagnosis, pathogenesis, prevention, care

Main publications

• Nagot N, Kankasa C, Tumwine JK, Meda N, Hofmeyr GJ, Vallo R, Mwiya M, Kwagala M, Traore H, Sunday A, Singata M, Siuluta C, Some E, Rutagwera D, Neboua D, Ndeezi G, Jackson D, Maréchal V, Neveu D, Engebretsen IM, Lombard C, Blanche S, Sommerfelt H, Rekacewicz C, Tylleskär T, Van de Perre P, for the ANRS 12174 Trial Group. Extended pre-exposure prophylaxis with lopinavir–ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial. Lancet 2016; 387: 566-73.
• Low AJ, Nagot N, Weiss HA, Konate I, Kania D, Segondy M, Meda N, Van de Perre P, Mayaud P. Herpes simplex virus type-2 (HSV-2) cervico-vaginal shedding among women living with HIV-1 on antiretroviral therapy in Burkina Faso: an 8-year longitudinal study. J Infect Dis 2016; 213: 731-7.
• Badiou S, Tuaillon E, Viljoen J, Escudié JB, Cristol JP, Newell ML, Van de Perre P, Neveu D. Association between breast milk fatty acids and HIV-1 transmission through breastfeeding. Prostaglandins Leukot Essent Fatty Acids 2016; 105: 35-42.
• Sanosyan A, Rutagwera D, Moles JP, Bolloré K, Periès M, Kankasa C, Mwiya M, Tylleskär T, Nagot N, Van de Perre P, Tuaillon E for  the ANRS 12174 Trial Group. Increased Epstein-Barr virus in breast milk occurs with subclinical mastitis and HIV shedding. Medicine 2016, in press.
• Viljoen J, Tuaillon E, Nagot N, Danaviah S, Peries M, Padayachee P, et al. Cytomegalovirus, and possibly Epstein-Barr virus, shedding in breast milk is associated with HIV-1 transmission by breastfeeding. AIDS. 2015 Jan 14;29(2):145-53.
• Simao D, Pinto C, Piersanti S, Weston A, Peddie CJ, Bastos AE, et al. Modeling human neural functionality in vitro: three-dimensional culture for dopaminergic differentiation. Tissue Eng Part A. 2015 Feb;21(3-4):654-68.
• Ngou J, Gilham C, Omar T, Goumbri-Lompo O, Doutre S, Michelow P, et al. Comparison of analytical and clinical performances of the digene HC2 HPV DNA assay and the INNO-LiPA HPV genotyping assay for detecting high-risk HPV infection and cervical neoplasia among HIV-positive African women. J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):162-8.
• Kania D, Truong TN, Montoya A, Nagot N, Van de Perre P, Tuaillon E. Performances of fourth generation HIV antigen/antibody assays on filter paper for detection of early HIV infections. J Clin Virol. 2015 Jan;62:92-7.
• Mennechet F, Tran TTP, Eichholz K, Van de Perre P, Kremer EJ. Ebola virus vaccine : benefit and risks of adenovirus-based vectors. Expert Rev Vaccines 2015; 1: 1-8.
• Bernard E, Hamel R, Neyret A, Ekchariyawat P, Moles JP, Simmons G, et al. Human keratinocytes restrict chikungunya virus replication at a post-fusion step. Virology. 2015 Feb;476:1-10.